Vorinostat in combination with bortezomib for the treatment of multiple myeloma in people who have received at least one prior therapy
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 November 2011
Topic area
  • Cancer

Scoped as part of Batch 20

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: Lori Farrar
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
9 May

The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for vorinostat in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual